AGIO · Transaction Mar 3, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · AGIO
-3.72% · -$1.18 · Vol 1.1M
After hours · updated 16:23:29 ET
Agios Pharmaceuticals Inc
Biotechnology
$30.54
Veridion Score
BETALOW CONF · 6/6 factorsStale score · Wed Aug 5 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET · AGIO
MethodologyAGIO
Agios Pharmaceuticals Inc
Stale score · Wed Aug 5 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET
NEUTRAL
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 6/6 factors with data · Stale score · Wed Aug 5 · completed session · 23h old · Scheduled each trading day · Markets closed · resumes Fri 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is AGIO moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Agios Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
2013
Employees
540
Country
US
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$31.44
Day high
$32.57
Day low
$31.44
Previous close
$31.72
52W high
$45.49
-32.86% from high
52W low
$22.34
35% of range
Market cap
$1.9B
EPS
$-7.0900
Beta
0.35
Shares out
59.7M
Volume
1.1M
0.86× rel vol
Avg volume
1.2M
VWAP
$32.04
Price history computed in-house
1W
-6.75%
1M
-30.61%
3M
+9.90%
1Y
-19.03%
YTD
+12.20%
SMA 50 $34.43 · below
SMA 200 $31.43 · below
52W position 35%
AGIO overview
Related filings and maps
Public disclosures
Congress activity in AGIO
Official filing ↗
AGIO · Transaction Dec 11, 2025 · Filed Jan 12, 2026 · $1,001 to $15,000
AGIO · Transaction Apr 17, 2025 · Filed May 6, 2025 · $1,001 to $15,000
AGIO · Transaction Jan 29, 2025 · Filed Feb 11, 2025 · $1,001 to $15,000
Agios Pharmaceuticals, Inc. - Common Stock · Transaction Jan 24, 2024 · Filed Feb 15, 2024 · $1,001 to $15,000
Federal contracts
AGIO contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AGIO in this window.
Lobbying spend
AGIO lobbying filings, year to date.
Registered lobbying filings matched to Agios Pharmaceuticals Inc.
$140.0K
Refresh interval: 12hSource: LDA disclosure filings
Health Issues
Medical/Disease Research/Clinical Labs
Medicare/MedicaidHealth Issues
Filing
$70.0K
AGIOS PHARMACEUTICALS
AGIOS PHARMACEUTICALS
Apr 17, 2026
Filing
$30.0K
AGIOS PHARMACEUTICALS
AGIOS PHARMACEUTICALS
Jul 20, 2026
Filing
$20.0K
AGIOS PHARMACEUTICALS
AGIOS PHARMACEUTICALS
Jan 20, 2026
Analyst ratings
Sovereign unlock shows live analyst consensus for AGIO.
Options
Sovereign unlock shows live options positioning for AGIO.